North Brunswick, NJ – According to filings with the U.S. Securities and Exchange Commission, Fidelis Pharmaceuticals is raising $5,129,692.00 in new funding. Sources indicate as part of senior management Chief Operating Officer, Barry Levinson played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Fidelis Pharmaceuticals
Fidelis Pharmaceuticals, LLC, offers exceptional expertise in the acquisition, development, and marketing of unique pharmaceutical formulations that meet specialized veterinary needs. Ethiqa XR is the only pharmaceutical grade extended-release buprenorphine specifically developed for the control of post-procedural pain in mice and rats. Ethiqa XR provides up to 72 hours of pain relief with just one injection. Fidelis Pharmaceuticals is a privately held U.S.-based company serving the world from the Northeast pharmaceutical corridor: Company headquarters is located in New Jersey. Ethiqa XR is manufactured in Pennsylvania. Supply chain sources and manufacturing sites and operations are in full compliance with current Good Manufacturing Practices (cGMPs) regulated by the FDA. Dedicated to providing products that are indexed by the FDA.

To learn more about Fidelis Pharmaceuticals, visit http://fidelisrx.com/

Contact:
Barry Levinson, Chief Operating Officer
833-384-4729
https://www.linkedin.com/in/barry-levinson-91141/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved